- $9.68bn
- $8.81bn
- $570.40m
- 100
- 22
- 83
- 78
Annual income statement for Doximity, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 207 | 344 | 419 | 475 | 570 |
| Cost of Revenue | |||||
| Gross Profit | 176 | 304 | 366 | 425 | 515 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 154 | 230 | 294 | 312 | 343 |
| Operating Profit | 53.3 | 114 | 125 | 164 | 228 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 57.8 | 114 | 133 | 185 | 264 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 50.2 | 155 | 113 | 148 | 223 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 50.2 | 155 | 113 | 148 | 223 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 21.6 | 133 | 113 | 148 | 223 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.121 | 0.698 | 0.529 | 0.748 | 1.12 |